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Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individu-
als, but little is known about the prevalence and evolution of this antibody response during the course of HIV-1 infection.
We analyzed the sera of 113 HIV-1 seroconverters from three cohorts for binding to a panel of gp120 core proteins and
their corresponding CD4bs knockout mutants. Among sera collected between 99 and 258 weeks post-HIV-1 infection, 88%
contained antibodies to the CD4bs and 47% contained antibodies to resurfaced stabilized core (RSC) probes that react
preferentially with broadly neutralizing CD4bs antibodies (BNCD4), such as monoclonal antibodies (MAbs) VRC01 and
VRC-CH31. Analysis of longitudinal serum samples from a subset of 18 subjects revealed that CD4bs antibodies to gp120
arose within the first 4 to 16 weeks of infection, while the development of RSC-reactive antibodies was more varied, occur-
ring between 10 and 152 weeks post-HIV-1 infection. Despite the presence of these antibodies, serum neutralization medi-
ated by RSC-reactive antibodies was detected in sera from only a few donors infected for more than 3 years. Thus, CD4bs
antibodies that bind a VRC01-like epitope are often induced during HIV-1 infection, but the level and potency required to
mediate serum neutralization may take years to develop. An improved understanding of the immunological factors associ-
ated with the development and maturation of neutralizing CD4bs antibodies during HIV-1 infection may provide insights
into the requirements for eliciting this response by vaccination.
A major goal of HIV-1 vaccination is to elicit antibodies thatinactivate or neutralize the majority of circulating HIV-1
strains. These potentially protective antibodies target the HIV-1
spike, which is composed of a trimer of noncovalently linked sur-
face glycoprotein (gp120) and transmembrane protein (gp41)
molecules. While most HIV-1 envelope glycoprotein (Env)-con-
taining candidate vaccines generate robust levels of Env-specific
antibodies, these antibodies neutralize only a minority of HIV-1
strains. In contrast, the sera of some HIV-1-infected subjects con-
tain potent and broadly reactive neutralizing antibodies. Detailed
analysis of such sera has provided information about the viral
epitopes targeted by neutralizing antibodies (2, 14, 16, 17, 28, 32,
37). In addition, the recent isolation of numerous broadly reactive
neutralizing monoclonal antibodies (MAbs) and their liganded
structures has helped to define the relatively conserved regions of
Env that are vulnerable to antibody neutralization. These epitopes
include the membrane-proximal region (MPER) of gp41 (6, 23,
24) and several regions on gp120, including glycan-containing
regions at the base of variable regions 1 and 2 (V1V2) (3, 19, 36)
and the base of V3 (25, 35) and an epitope within the CD4 binding
site (CD4bs) of gp120 (9, 29, 41, 44).
Until recently, only one known CD4bs-directed neutraliz-
ing MAb was able to neutralize primary HIV-1 strains. Mono-
clonal antibody b12 was first described in 1994 (5), and its
crystal structure bound to the core of gp120 was resolved in
2007 (45). We recently isolated MAb VRC01, which is capable
of neutralizing about 90% of HIV-1 strains (39), and in the last
2 years, additional broadly neutralizing CD4bs (BNCD4)
MAbs have been isolated from a few HIV-1-infected donors
whose sera were known to contain highly potent neutralizing
activity (29, 41). The genetic and structural analysis of these
antibodies has identified several common characteristics: the
heavy chains of these CD4bs MAbs use variable gene VH1-2 or
the closely related VH1-46, and both the heavy and light chains
contain high levels of somatic mutations that are required for
effective neutralization.
The existence of these BNCD4 MAbs provides proof of concept
that the immune system can produce potent antibodies to this
conserved region of Env, but all MAbs isolated to date were from
a few highly selected donors who had been HIV-1 infected for at
least several years. In addition, broadly reactive serum neutraliza-
tion is rarely detected before 2 to 3 years of HIV-1 infection, and it
is not clear if BNCD4 antibodies would be present in some donors
prior to this time but not detected in current neutralization assays.
We therefore used a set of well-characterized recombinant core
gp120 probes to analyze the prevalence and the time course of
BNCD4-related antibodies in three cohorts of HIV-1 seroconvert-
ers. We previously described versions of gp120 core constructs
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(containing deletions of V1, V2, and V3 and truncations at the N
and C termini) that react with most known CD4bs MAbs (15, 16),
as well as the design of a resurfaced stabilized core (RSC3) that was
used to isolate MAb VRC01 (39). Here, we used these gp120 core
and RSC3 proteins to detect antibodies antigenically related to
MAb VRC01 in the sera of HIV-1-infected subjects. We analyzed
a total of 113 sera from the Center for HIV/AIDS Vaccine Immu-
nology (CHAVI), the Center for the AIDS Programme of Re-
search in South Africa (CAPRISA), and Amsterdam cohorts to
determine the prevalence of CD4bs antibodies and further studied
the evolution of this response in a subset of 18 subjects.
MATERIALS AND METHODS
Human subjects. The sera and plasmas used in this study were from three
previously described HIV-1 seroconverter cohorts. The 45 subjects from
the CAPRISA 002 acute-infection cohort were women from South Africa
(13); of the 30 subjects from the CHAVI 001 cohort (21 male and 8 fe-
male), 14 were from sites in Malawi, 11 from South Africa, and 5 from the
United States (12, 18, 33), and 38 male subjects were in the Amsterdam
Cohort (10). In the CAPRISA cohort, acute infection was diagnosed fol-
lowing a positive HIV-1 RNA PCR in the absence of HIV-1 antibodies or
detection of HIV-1 antibodies within 3 months of a previously negative
antibody test. The time of infection was defined as 14 days prior to a
positive RNA PCR assay or as the midpoint between the last HIV-1-sero-
negative test and the first seropositive test. In the Amsterdam cohort,
subjects were tested approximately every 3 months, and infection was
defined as the midpoint between the last HIV-1-seronegative time point
and the first positive enzyme-linked immunosorbent assay (ELISA). In
the CHAVI 001 cohort, high-risk subjects were screened for HIV-1 infec-
tion by ELISA, Western blotting, and plasma RNA and categorized using
the Fiebig staging classification of acute infection, which allows an esti-
mation of the time of initial HIV-1 infection (11, 12, 20, 33). Subjects were
included in this analysis if their Fiebig stage was calculated to be between
1 and 5 at screening, except for CH018, who was Fiebig 6 (11). The sam-
ples used for initial screening assays depended on the maturity of the
seroconverter cohort, and the median time points were 99, 147, and 258
weeks postinfection in the CHAVI, CAPRISA, and Amsterdam cohorts,
respectively. All donor sera analyzed were from time points prior to the
initiation of antiretroviral therapy.
Probes for detection of CD4bs-specific antibodies. To detect anti-
bodies to the CD4bs region of gp120, we used several well-characterized
recombinant gp120 core glycoproteins and their respective CD4bs knock-
out mutants. The YU2-based gp120 core, which lacks variable regions V1,
V2, and V3 and is truncated at the N- and C-terminal regions, and its
D368R mutant have been described previously (15–17). The replacement
of aspartic acid with an arginine at position 368 within the CD4 binding
pocket of gp120 has been shown to reduce or knock out binding of most
CD4bs MAbs (31, 42). The resurfaced stabilized gp120 core (RSC3), along
with its RSC3 371I mutant (39), has been described previously. The
RSC3 protein is a resurfaced version of the stabilized core of gp120 (HXB2
Ds12F123) (8, 45). Removal of the isoleucine at position 371 of RSC3 was
shown to reduce binding by b12 and VRC01, and this probe pair was used
to isolate the VRC01 MAb (39). The RSC3/G367R probe was designed,
based on modeling of available crystal structures, to further improve the
specificity of RSC3 for VRC01-like MAbs by abrogating or substantially
reducing binding to MAbs b12 and b13 while maintaining VRC01 bind-
ing. RSC3 371I/P363N was designed as an additional CD4bs knockout
mutant of RSC3. Of note, all the RSC3 probes were designed to maintain
binding to MAb 2G12, which reacts with outer-domain glycans. Thus,
both the RSC3 probes and their CD4bs knockout mutants reacted simi-
larly with 2G12, and the MAb served as a positive control in ELISAs.
HIV-1 core protein binding assays. ELISAs were performed as previ-
ously described (41). Briefly, 96-well ELISA plates were coated with 2
g/ml of the specified recombinant protein in phosphate-buffered saline
(PBS) overnight at 4°C. The following day, the plates were blocked with
B3T buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 3.3% fetal
bovine serum, 2% bovine albumin, 0.07% Tween 20) and incubated with
4-fold serial dilutions of heat-inactivated sera starting at a dilution of
1:100, followed by peroxidase-conjugated goat anti-human IgG antibody
(Jackson ImmunoResearch). All incubations were for 1 h at 37°C, and all
volumes were 100 l, except for blocking, which was 200 l. The plates
were washed between incubations with 0.1% Tween 20 in PBS, detected
using SureBlue TMB substrate (Kirkegaard & Perry Laboratories), and
subsequently read at 450 nm. Endpoint titers were calculated based on the
final reciprocal serum dilution with a background-corrected optical den-
sity (OD) greater than or equal to 0.1. Sera were considered reactive when
the reciprocal endpoint titer was greater than 200. Anti-gp120 MAb 2G12
was purchased from Polymun Scientific Inc. (Vienna, Austria) (34), and
CD4-induced (CD4i) MAb 17b was provided by James Robinson (Tulane
University) (30). Anti-CD4bs MAbs were provided as follows: F91 was
provided by James Robinson (Tulane University, New Orleans, LA) (22),
MAb F105 was provided by Marshall Posner (Dana Farber Cancer Insti-
tute, Boston, MA) (27), MAb b6 was provided by Dennis Burton (Scripps
Research Institute, La Jolla, CA) (1), MAb m18 IgG was provided by
Dimiter Dimitrov (National Cancer Institute, Frederick, MD) (43), and
HJ16 was provided by Davide Corte (Institute for Research in Biomedi-
cine, Bellinzona, Switzerland) (7). The heavy- and light-chain genes of
MAbs b12 (5), b13 (1), VRC01 (39), VRC-PG04, VRC-CH31 (41),
NIH45-46, 3BNC60, 3BNC117, 12A12, and 12A21 (29) were synthesized
and cloned into the expression vector VRC-1012 containing a modified
cytomegalovirus immediate-early 1 gene promoter (CMV/R promoter)
and the coding sequence for the constant region of IgG1. Full-length IgGs
were expressed from transient transfection of 293F cells and purified by
affinity chromatography using HiTrap Protein A HP Columns (GE
Healthcare).
HIV-1 neutralization assays. HIV-1 neutralization was measured us-
ing a single round of infection by Env pseudoviruses and Tzm-bl target
cells as previously described (38, 40). CD4bs-directed neutralization was
assessed in a neutralization competition assay format using specific pro-
tein probes to block antibody-mediated neutralization, as previously de-
scribed (39). Briefly, 25 g/ml of RSC3 or 25 g/ml of the mutant RSC3
371I/P363N or PBS was incubated with sera serially diluted 4-fold from
1:20 for 15 min, after which 40 l of HXBc2 pseudovirus (multiplicity of
infection [MOI], approximately 0.1) was added for a 30-min incubation.
Tzm-bl cells were added at a concentration of 104 per well, and the single-
round infection proceeded for 48 h. All incubations were at 37°C, and
each infection was performed in duplicate wells of a 96-well flat-bottom
culture plate. Neutralization curves were fitted by nonlinear regression
using a four-parameter hill slope equation programmed into JMP statis-
tical software (JMP 5.1; SAS Institute Inc., Cary, NC). The 50% inhibitory
dilutions (ID50s) were reported as the reciprocal serum dilutions required
to inhibit infection by 50%. CD4bs-directed activity was calculated as a
30% reduction in the ID50 values of the sera in the presence of RSC3
compared to RSC3 371I/P363N.
RESULTS
Probes designed to preferentially react with broadly neutraliz-
ing CD4bs antibodies. The known CD4bs MAbs bind strongly to
recombinant gp120, but only a subset of these MAbs are able to
access the CD4bs of the native viral spike and potently neutralize
primary HIV-1 isolates. These neutralizing CD4bs antibodies in-
clude b12, HJ16, VRC01, VRC-PG04, and VRC-CH31 (5, 7, 41),
as well as MAbs from several additional donors that were recently
described (29). The prototypical MAbs F105, m18, b6, b13, and
F91 are examples of CD4bs MAbs with neutralization limited to a
subset of tier 1 HIV-1 strains. Here, we evaluated the abilities of
various protein probes to distinguish between these specificities.
The gp120 core has been previously shown to bind CD4bs-di-
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rected antibodies (8, 16), and we confirmed this pattern of reac-
tivity. All CD4bs MAbs tested reacted strongly with gp120 core by
ELISA and, with the exception of MAbs b6 and HJ16, bound less
efficiently to the D368R mutant (Table 1). In contrast, the RSC3
protein did not bind to the weakly neutralizing CD4bs MAbs
F105, F91, and b6 but maintained strong reactivity to the broader
and more potently neutralizing MAbs, such as b12 and VRC01.
Since RSC3 also retained reactivity to MAbs b13 and m18, which
are MAbs with limited neutralization breadth, we designed addi-
tional mutant versions of RSC3. One such mutant, RSC3/G367R,
was designed to create a steric clash for MAb b12 and b13 binding
while causing little interference with VRC01 binding. ELISA data
verified that the RSC3/G367R probe displayed reduced binding to
b12, b13, and m18 while maintaining strong ELISA reactivity to
VRC01. The RSC3/G367R probe also maintained modestly strong
binding to the other BNCD4 MAbs of VH1-2 origin (VRC-PG04,
VRC-CH31, NIH45-46, 3BNC60, 3BNC117, and 12A12), with
the exception of MAb 12A21 (Table 1). Thus, the RSC3/G367R
mutant was a useful adjunct to RSC3 in antigenically distinguish-
ing most BNCD4 MAbs from the weaker neutralizing group. We,
therefore used the gp120 core, as well as these resurfaced core
protein probes, to detect CD4bs antibodies in sera and to further
discriminate antibody specificities related to VRC01 and BNCD4
MAbs.
CD4bs antibodies are commonly elicited in HIV-1 infection.
The time period of longitudinal follow-up for the three HIV-1
cohorts varied from approximately 99 weeks (CHAVI) to greater
than 250 weeks (Amsterdam). Since we were interested in the
evolution of the CD4bs antibody response, we first screened sera
obtained from a late time point in each cohort. Thus, the 30
CHAVI sera were obtained at 99 weeks postinfection, the 45
CAPRISA sera were from 147 weeks, and the 38 Amsterdam sera
were from 258 weeks postinfection. All 113 sera were screened
by ELISA for reactivity to the gp120 core and RSC3 protein probes
described above. A serum was considered reactive to a specific
probe if its endpoint titer was greater than 1:200 and there was a
greater than 2.5-fold loss of activity on the cognate CD4bs mutant.
A majority of sera in each cohort contained CD4bs antibodies to
the gp120 core, indicating the overall immunogenicity of the
CD4bs during infection (Fig. 1A). In each cohort, the prevalence
of serum reactivity to the more specific RSC3 probes was lower
than the overall prevalence of core CD4bs antibodies. Since most
BNCD4 MAbs reacted to both RSC3 and RSC3/G367R (Table 1),
we classified sera with reactivity to both of these proteins as con-
taining antibodies similar to this group of broadly neutralizing
VRC01-like antibodies that derive from the VH1-2 heavy-chain
germ line gene. Based on this criterion, sera with VRC01-like
binding activity were found in 30%, 31%, and 79% of the CHAVI,
CAPRISA, and Amsterdam cohorts, respectively. It is notable that
the Amsterdam sera were obtained approximately 5 years postin-
fection compared to less than 3 years for CAPRISA and less than 2
years for the CHAVI cohort. Among those subjects that made any
CD4bs antibody response (i.e., gp120 core reactive), the percent-
ages that also made RSC3-reactive antibodies were 22%, 34%, and
81% in the CHAVI, CAPRISA, and Amsterdam cohorts, respec-
tively (Fig. 1B). This observation suggests that a longer time of
infection may foster the evolution of CD4bs antibodies that attain
reactivity to RSC3.
Since the development of serum neutralizing antibody breadth
has been associated with the level of plasma viremia (13, 26, 28),
TABLE 1 Antigenic profile of proteins used to characterize CD4bs antibody specificity
Antibodya
Bindingd
YU2 gp120-based proteinsb Resurfaced core proteinsc
Type Name gp120 core gp120 core D368R RSC3 RSC3/G367R RSC3 371I RSC3 371I/ P363N
CD4bs F105      
F91      
m18      
b6      
b13      
b12      
VRC01      
VRC-PG04      
VRC-CH31      
NIH45-46      
3BNC60      
3BNC117      
12A12      
12A21      
HJ16      
CD4i 17b      
Glycan 2G12      
a Antibodies are grouped by category: CD4bs, CD4i, and glycan reactive (Glycan). Of the CD4bs MAbs, VRC01, VRC-PG04, VRC-CH31, NIH45-46, 3BNC60, 3BNC117, 12A12,
and 12A21 are all broadly neutralizing antibodies derived from the VH1-2*02 germ line allele.
b Mutant residue numbers are based on the HXBc2 sequence, and gp120 D368R is the CD4bs knockout mutation.
c Mutant residue numbers are based on the HXBc2 sequence. RSC3 371I has an isoleucine deletion at position 371, and RSC3 371I/P363N contains an additional P363N
mutation. Both were designed as CD4bs knockout versions of RSC3.
d Binding was categorized based on ELISA OD at 450 nm (OD450) values at the highest concentration of antibody tested (5 g/ml) and the 50% effective concentration (EC50)
values as follows: , OD450  3.0 and EC50  0.10; , OD450  3.0 and EC50  0.10; , 1.0  OD450  3.0; , 0.2  OD450  1.0; and , OD450  0.2.
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we analyzed the association between the plasma viral load and the
development of RSC3-reactive CD4bs antibodies. Among the 113
antiretroviral-naïve subjects, there was no association between the
viral-load set point (the mean viral load between 24 weeks postin-
fection and the time of serum screening) or the mean viral load 1
year prior to serum screening and the presence of RSC3 binding
antibodies in sera (Fig. 2), nor was there a correlation between the
peak viral load (analyzed in a subset of 47 subjects) and the devel-
opment of RSC3-reactive antibodies. An analysis of peripheral
CD4 T cell levels also found no association, though the large ma-
jority of subjects had CD4 T cell levels greater than 300/l (data
not shown). Thus, although the level of viremia may play a role in
the development of neutralizing antibodies, and perhaps even
BNCD4-like antibodies, there was no association between the vi-
ral load and the presence of RSC3 binding antibodies in these
three cohorts.
Evolution of the CD4bs antibody response. To assess the ki-
netics of CD4bs antibody development, we analyzed longitudinal
serum samples for six subjects from each cohort whose sera con-
tained RSC3-reactive antibodies at a later time point (Table 2).
CD4bs antibodies that bind to gp120 core were detectable within
16 weeks postinfection in 15 of 18 subjects (Fig. 3). Among the six
CHAVI subjects for whom we had the earliest time points postin-
fection, serum CD4bs antibodies arose between 7 and 15 weeks
after infection, in agreement with previously published work sug-
gesting the early, but not immediate, development of CD4bs an-
tibodies (33). CD4bs antibodies that bound to the RSC3 probes
generally developed after these core antibodies, ranging from as
early as 10 weeks (CH058) to as late as 152 weeks (CAP274)
postinfection. Two subjects from the CHAVI cohort, CH058 and
CH505, demonstrated a common pattern of antibody develop-
ment in which CD4bs core antibodies were detected first, followed
by RSC3-reactive CD4bs antibodies; however, other patterns were
observed (Fig. 3). Overall, these data suggest that CD4bs antibod-
ies occur in most subjects and develop early, while antibodies that
bind to the more precise neutralizing epitope defined by VRC01
and related BNCD4 MAbs develop later, although usually within
the first 2 years of infection.
Serum neutralizing activity. Subjects from the CHAVI and
CAPRISA cohorts whose sera exhibited the antigenic profile of
BNCD4 antibodies (reactivity to the RSC3 and RSC3/G367R
probes) (Fig. 1A) were screened against a panel of 6 heterologous
Env pseudoviruses (Fig. 4). The 23 sera analyzed were from the
same time point shown in Fig. 1 (medians, 99 weeks postinfection
for the CHAVI subjects and 147 weeks postinfection for the
CAPRISA subjects). These sera displayed relatively modest neu-
tralization potency and breadth. This finding is consistent with
prior published data demonstrating that neutralization breadth
generally develops after 2 to 3 years of HIV-1 infection (13, 21, 28).
The lack of potent neutralization in these sera, which contain
RSC3-reactive antibodies, suggests that this antibody specificity
has not yet achieved either the affinity or serum concentration
necessary to mediate broad virus neutralization. Unfortunately,
the volume of sera required for these neutralization assays was not
available from the Amsterdam cohort. Since most of the sera neu-
tralized the sensitive HXBc2 viral strain, we performed competi-
tion neutralization assays on all 53 RSC3-reactive sera to deter-
mine if the virus neutralization was mediated by CD4bs
antibodies. Protein competition assays were performed using the
RSC3 and RSC3 371I/P363N proteins, which do not bind CD4
and therefore do not block viral entry (39, 41). A 30% net reduc-
tion in the serum ID50 value after incubation with RSC3 (com-
pared to RSC3 371I/P363N) was considered evidence of CD4bs-
directed neutralization. None of the CHAVI or CAPRISA sera
contained detectable CD4bs-directed neutralization activity, but 9
sera from the Amsterdam cohort had detectable CD4bs neutraliz-
ing antibodies that were blocked by RSC3 (Fig. 5).
FIG 2 Lack of association between plasma viral load and RSC3-reactive
CD4bs antibodies. RSC3-positive sera were those reactive with both RSC3
and RSC3/G367R. The viral load (VL) was calculated as the geometric
mean of VL values between 24 weeks postinfection and the time of screen-
ing (set point), VL values 52 weeks prior to screening (prior), or the peak
viral load in a subset of donors with early sampling time points (peak). The
box plot shows the median values and the 25% and 75% quartiles. The
range and outliers are shown by the bars and circles, respectively. neg.,
negative; pos., positive.
FIG 1 Prevalence of CD4 binding site antibodies among donors in three
HIV-1 seroconverter cohorts. (A) The percentages of donors reacting by
ELISA with the indicated protein probes are shown by the colored bars. A
2.5-fold or greater difference in serum binding to the wild type compared to
the corresponding CD4bs knockout mutant probe was considered positive.
For each cohort, the number of subjects analyzed (N) and the median time
post-HIV-1 infection are indicated. (B) Summary of percent positive serum
ELISA data for each core protein probe or the combination of both RSC3 and
RSC3/G367R. Samples reactive with both RSC3 and RSC3/G367R have bind-
ing profiles similar to those of BNCD4 MAbs. The last column indicates the
percentages of sera reactive with gp120 core that also reacted with both RSC3
and RSC3/G367R.
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DISCUSSION
The CD4bs of HIV-1 gp120 is a desirable target for vaccine design
because it is a highly conserved region of Env that interacts with
the host CD4 receptor and because MAbs to the CD4bs can po-
tently neutralize the large majority of HIV-1 strains. Thus, a major
aim of HIV-1 vaccination is to elicit BNCD4 antibodies similar to
those generated during HIV-1 infection. However, not all HIV-1-
infected individuals develop these neutralizing antibodies, and the
existing BNCD4 MAbs have been isolated from highly selected
individuals who were infected for a minimum of several years. In
this study, we sought to determine the prevalence of HIV-1-in-
fected subjects with serum antibodies similar to the known
BNCD4 MAbs. Since potent primary isolate neutralization may
take years to reach detectable serum levels, we used a set of gp120
probes to detect serum CD4bs antibodies with antigenic profiles
similar to those of VRC01 and related BNCD4 MAbs. In addition,
we studied the time course of development of general CD4bs- and
BNCD4-related antibodies and show that the latter antibody spec-
ificity occurs in a subset of those with CD4bs antibodies and de-
velops weeks to months later.
We used a set of well-characterized gp120 core and RSC3 pro-
tein probes, and their cognate CD4bs knockout mutants, to detect
serum antibodies. The antigenic profiles of these proteins were
confirmed with a panel of known MAbs, and preferential reactiv-
ity to the RSC3 and RSC3/G367R probes was shown to distinguish
most of the BNCD4 MAbs (e.g., VRC01, VRC-PG04, and VRC-
CH31) from the remainder of the CD4bs MAbs, which demon-
strated weak or no binding. However, it remains possible that the
RSC3/G367R probe reacts strongly with some as yet unidentified
non-broadly neutralizing CD4bs antibodies. As such, the use of
these probes is clearly an indirect measure of the presence of neu-
tralizing antibodies, such as VRC01. We have therefore attempted
to be cautious in our conclusions, referring to serum reactivity
patterns as evidence of antibody specificities that are similar to
those of known broadly neutralizing antibodies. The fact that
RSC3-reactive antibodies were detected in sera with weak HIV-1
neutralization activity suggests that either the level of RSC3-reac-
tive antibodies was too low to mediate neutralization or, as noted
above, that these antibodies were not sufficiently affinity matured
to mediate virus neutralization. Of note, we were able to confirm
the presence of CD4bs-directed neutralizing antibodies in some
subjects via serum RSC3 competition neutralization assays; how-
ever, the assay detects CD4bs neutralizing activity only when it
constitutes at least 30% of serum neutralization.
Overall, our data show that the CD4bs of gp120 is highly
immunogenic. More than 80% of the subjects studied had ev-
idence of such antibodies at time points 99 or more weeks
postinfection, and longitudinal studies indicated that CD4bs
antibodies were present within 16 weeks postinfection. How-
ever, a more detailed analysis suggests that the precise region of
the CD4bs bound by MAbs such as VRC01 is less immuno-
genic. At approximately 2 to 3 years postinfection, only 30%
and 31% of the CHAVI and CAPRISA subjects, respectively,
had CD4bs antibodies with specificities similar to those of
BNCD4 MAbs. This percentage may increase with the time of
infection, because 79% of the Amsterdam cohort (infected for
5 years) had the antibodies. The longitudinal sampling in a
subset of 18 seroconverters confirms the delayed appearance of
BNCD4-like antibodies, which often arose months after the
first appearance of core-directed CD4bs antibodies. It is possi-
ble that the different demographics and infecting viral clades
among the cohorts account for these differences, but since the
CD4bs is highly conserved, this seems unlikely. Of note, 21 of
the 38 sera from the Amsterdam cohort were included in our
study because there was some prior evidence of moderate neu-
tralizing activity and the remaining 17 sera did not show such
activity (10). The percentages of sera with RSC3 binding activ-
ity did not differ among these two sets of sera, and we do not
think this selection accounts for the higher RSC3 reactivity in
the cohort.
TABLE 2 Serum endpoint ELISA titers against protein probes used to characterize CD4bs reactivity
Subject Wka
Titer
YU2 core D368R Ratiob RSC3 RSC3 371I Ratiob RSC3/G367R RSC3 371I/P363N Ratiob
CH018 100 187,500 7,500 25 2,500 100 25 300 100 3.0
CH058 98 37,500 2,500 15 37,500 100 375 2,500 100 25
CH107 99 62,500 37,500 1.7 12,500 100 125 300 100 3.0
CH110 102 312,500 2,500 125 7,500 100 75 100 100 NC
CH505 101 102,400 400 256 6,400 100 64 100 100 NC
CH694 99 102,400 25,600 4.0 400 400 1.0 1,600 250 6.4
CAP188 145 102,400 400 256 4,000 1,600 2.5 6,400 250 26
CAP217 154 64,000 25,600 2.5 1,600 100 16 400 100 4.0
CAP222 148 256,000 4,000 64 100 100 n/c 100 100 NC
CAP265 158 102,400 6,400 16 4,000 100 40 400 100 4.0
CAP274 152 102,400 6,400 16 400 100 4.0 100 100 NC
CAP282 156 1024,000 16,000 64 1,000 100 10 100 100 NC
Amsterdam 03 258 1638,400 102,400 16 409,600 16,000 25.6 64,000 250 256
Amsterdam 10 259 409,600 102,400 4.0 1,600 400 4.0 1,000 400 2.5
Amsterdam 13 265 409,600 25,600 16 1,600 400 4.0 1,600 100 16
Amsterdam 18 263 409,600 25,600 16 25,600 6,400 4.0 4,000 1,600 2.5
Amsterdam 21 167 102,400 6,400 16 102,400 1,600 64 6,400 1,000 6.4
Amsterdam 25 232 409,600 64,000 6.4 25,600 1,000 25.6 1,000 400 2.5
a Number of weeks post HIV-1 infection, as defined in Materials and Methods.
b Ratio of previous two endpoint titers. Ratio was not calculated (NC) when reciprocal serum endpoint titers were both 200.
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The virological or immunological characteristics that are asso-
ciated with the development of neutralizing antibodies to the
CD4bs remain to be elucidated. In our cohorts of antiretroviral-
naive subjects, there was no association between the peak or set
point plasma viral load and the presence of RSC3-reactive anti-
bodies. Thus, it is not yet clear why only a subset of HIV-1-in-
fected individuals make antibodies that bind epitopes similar to
those of BNCD4 MAbs, and it is possible that virologic or host
FIG 3 Kinetics of the CD4 binding site antibody responses in 18 selected subjects. Serial longitudinal serum samples from six subjects from each cohort were
analyzed. The ELISA endpoint titers (y axis) are graphed for multiple weeks after HIV-1 infection (x axis). The line colors correspond to the protein probes shown
in Fig. 1. The solid lines show reactivity to the probe, while the dashed lines indicate the corresponding CD4bs knockout mutant. The first time point reactive with
RSC3 is indicated by the vertical dotted lines.
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genetic factors play a role. Some subjects that can make BNCD4
can also make broadly neutralizing V2V3-directed antibodies (4,
32), suggesting that common factors may affect the ability to make
broadly neutralizing antibodies.
Among subjects in this study who generated BNCD4-like an-
tibody responses, the longitudinal data suggested that weeks to
months were required for the induction of these antibodies. This
finding may correspond to the high level of affinity maturation
that is characteristic of CD4bs neutralizing antibodies with heavy-
chain nucleotide substitution rates of 24% to 31% compared to
germ line antibody gene sequence (29, 39). Thus, it is possible that
the delayed induction of BNCD4-like antibodies is due in part to
the level of affinity maturation required for the antibody to ac-
quire potent neutralization activity. To test this hypothesis, MAbs
from these subjects could be isolated and analyzed. Once the gene
family derivation of specific neutralizing MAbs is known, it
should be possible to use deep-sequencing technologies to track
the genetic footprint of the antibody lineage from early in infec-
tion through the time point of potent neutralization. Such studies
could provide insights into the pathway for the development of
neutralizing antibodies to the CD4bs and could be applied simi-
larly to understand the evolution of antibodies to other neutral-
ization epitopes. This highlights the value of HIV-1 seroconverter
cohorts that acquire samples early after infection and that follow
subjects over time to the development of broadly neutralizing an-
tibodies.
In summary, these data from three HIV-1 seroconverter
cohorts provide the first prospective estimates of the preva-
lence of neutralizing antibodies to the CD4bs of gp120. While
this region of the HIV-1 Env is highly immunogenic overall,
the precise region bound by neutralizing antibodies, such as
VRC01, VRC-PG04, and VRC-CH31, is less immunogenic, and
induction of such antibodies is delayed compared to other
CD4bs antibody specificities. Future studies to understand im-
munologic factors and antibody maturation pathways associ-
ated with the successful development of BNCD4 antibodies
may provide insights for the design of improved immunogens
and immunization strategies.
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